Company Bellerophon Therapeutics LLC Nasdaq
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- | - |
05-02 | North American Morning Briefing : Stock Futures -2- | DJ |
04-25 | North American Morning Briefing : More Tech -2- | DJ |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Craig Jalbert
CEO | Chief Executive Officer | 63 | - |
Martin Dekker
CTO | Chief Tech/Sci/R&D Officer | 51 | 15-01-28 |
Edwin L. Parsley
CTO | Chief Tech/Sci/R&D Officer | 63 | - |
Bobae Kim
LAW | General Counsel | 42 | 22-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Naseem Amin
CHM | Chairman | 62 | 15-06-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 12,232,648 | 10,394,477 ( 84.97 %) | 0 | 84.97 % |
Company contact information
Bellerophon Therapeutics, Inc.
184 Liberty Corner Road Suite 302
07059, Warren
+908 574 4770
http://www.bellerophon.comSector
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |
- Stock Market
- Equities
- BLPH Stock
- Stock
- Company Bellerophon Therapeutics LLC